Vitamin D supplementation may benefit hypercholesterolaemia patients
Supplementation with vitamin D appears to help reduce the serum concentration of total and low-density lipoprotein cholesterol (LDL-C) and triglyceride but not high-density lipoprotein cholesterol (HDL-C), suggesting its usefulness for mitigating the risk of cardiovascular disease (CVD) in patients with hypercholesterolaemia, according to the results of a meta-analysis.
The meta-analysis included 41 randomized clinical trials (RCTs) comprising 3,434 participants (mean age, 55 years; 63.4 percent female), among whom 1,699 received vitamin D supplementation and 1,735 placebo. Approximately 24 percent of the trials had follow-up duration of >6 months, whereas the majority (76 percent) had shorter follow-up.
Of the trials, 21 involved participants with diabetes, 13 included apparently healthy participants and three were conducted on those who were obese or overweight. Mean vitamin D supplement per day was 2,795 IU.
Pooled data revealed that compared with placebo, vitamin D supplementation produced reductions in the following: total cholesterol (standardized mean difference [SMD], –0.17, 95 percent CI, –0.28 to –0.06; I2, 54.6 percent), LDL-C (SMD, –0.12, –0.23 to –0.01; I2, 52 percent), triglycerides (SMD, –0.15, –0.24 to –0.06; I2, 32.9 percent). On the other hand, the effect of supplementation on HDL-C was not meaningfully different (SMD, –0.10, –0.28 to 0.09).
The improvements observed in total cholesterol and triglycerides were more pronounced in participants who were vitamin D-deficient at baseline.
The present data indicate that clinicians may consider supplementing regular cholesterol treatments with vitamin D in patients with hypercholesterolaemia and vitamin D deficiency.